To evaluate the vaccine, Dr. Convit and his team apply the immunotherapy against leishmaniasis in 11532 patients with American Cutaneous Leishmaniasis in Venezuela, and observe a mean of 95.7% of cured patients. They publish an article with these results, and based on this success, the immunotherapy is applied in other countries of the region to treat patients with Cutaneous Leishmaniasis.